Your browser doesn't support javascript.
loading
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment.
Olkkola, Aleksi M; Tapaninen, Tuija; Tornio, Aleksi; Hauta-Aho, Milka; Lapatto-Reiniluoto, Outi; Neuvonen, Mikko; Kiiski, Johanna I; Neuvonen, Pertti J; Niemi, Mikko; Backman, Janne T.
Affiliation
  • Olkkola AM; Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
  • Tapaninen T; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Tornio A; Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
  • Hauta-Aho M; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Lapatto-Reiniluoto O; Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
  • Neuvonen M; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Kiiski JI; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
  • Neuvonen PJ; Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.
  • Niemi M; Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
  • Backman JT; Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Br J Clin Pharmacol ; 90(2): 557-567, 2024 02.
Article in En | MEDLINE | ID: mdl-37872104

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Triazoles / Adenine / Cytochrome P-450 CYP3A / Percutaneous Coronary Intervention Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Triazoles / Adenine / Cytochrome P-450 CYP3A / Percutaneous Coronary Intervention Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2024 Document type: Article Affiliation country: Country of publication: